Boehringer Explores ‘Dark Antigens’ With Enara In Potential $1bn Deal
Covers Novel Cancer Immunotherapy Targets And Therapies
Executive Summary
Announcing its first big pharma deal, the Oxford-based biotech says there could be more to come – with mRNA pioneers also interested in shining a light on hidden drug targets.
You may also be interested in...
Science Matters: Harnessing The Inherent Power Of MAIT Cells
Tapping into the interplay between gut microbiota and an underappreciated subset of T cells could lead to therapies in a range of diseases.
Deal Watch: Sanofi Teams Up With Biond On Novel Checkpoint Inhibitor
Days after buying Kymab, Sanofi partners with Israel’s Biond on IO candidate targeting ILT2. Gilead again tackles functional cure of hepatitis B in alliance with Vir.
Denmark's IO Vaccine Biotech Attracts Investor Interest
Copenhagen-based start-up IO Biotech has raised a hefty €127m from a group of VC investors to accelerate its IDO- and PD-L1 targeted immuno-oncology approaches to the treatment of cancer.